Zacks Investment Research Downgrades ANI Pharmaceuticals Inc. (ANIP) to Sell
ANI Pharmaceuticals Inc. (NASDAQ:ANIP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “
Several other equities research analysts also recently commented on the stock. TheStreet upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 26th. Guggenheim reiterated a “buy” rating and set a $80.00 target price (up previously from $65.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 5th. Oppenheimer Holdings Inc. boosted their target price on shares of ANI Pharmaceuticals from $65.00 to $71.00 and gave the company an “outperform” rating in a research report on Friday, August 5th. Finally, Citigroup Inc. upgraded shares of ANI Pharmaceuticals to an “outperform” rating and set a $65.00 target price on the stock in a research report on Tuesday, July 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $65.14.
Shares of ANI Pharmaceuticals (NASDAQ:ANIP) opened at 55.27 on Tuesday. The company has a market capitalization of $640.03 million, a PE ratio of 80.92 and a beta of 3.22. ANI Pharmaceuticals has a 52 week low of $26.80 and a 52 week high of $70.92. The firm’s 50-day moving average is $63.96 and its 200 day moving average is $58.64.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported $1.09 EPS for the quarter, topping the consensus estimate of $1.08 by $0.01. ANI Pharmaceuticals had a net margin of 7.28% and a return on equity of 21.84%. The business had revenue of $38.53 million for the quarter, compared to the consensus estimate of $34.34 million. During the same period last year, the company earned $0.80 EPS. The firm’s revenue was up 92.9% compared to the same quarter last year. On average, analysts anticipate that ANI Pharmaceuticals will post $4.06 earnings per share for the current fiscal year.
In related news, insider Arthur Przybyl sold 37,455 shares of the stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $66.97, for a total transaction of $2,508,361.35. Following the completion of the transaction, the insider now owns 200,788 shares in the company, valued at $13,446,772.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 31.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Fiera Capital Corp bought a new position in ANI Pharmaceuticals during the second quarter valued at $10,602,000. State Street Corp raised its position in ANI Pharmaceuticals by 62.5% in the second quarter. State Street Corp now owns 291,439 shares of the specialty pharmaceutical company’s stock valued at $16,272,000 after buying an additional 112,076 shares during the last quarter. Smith Asset Management Group LP bought a new position in ANI Pharmaceuticals during the second quarter valued at $3,334,000. BlackRock Fund Advisors raised its position in ANI Pharmaceuticals by 8.7% in the third quarter. BlackRock Fund Advisors now owns 718,640 shares of the specialty pharmaceutical company’s stock valued at $47,682,000 after buying an additional 57,809 shares during the last quarter. Finally, Healthcare Value Capital LLC raised its position in ANI Pharmaceuticals by 14.5% in the first quarter. Healthcare Value Capital LLC now owns 395,000 shares of the specialty pharmaceutical company’s stock valued at $13,296,000 after buying an additional 50,000 shares during the last quarter. Institutional investors own 49.02% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.